|Year : 2009 | Volume
| Issue : 2 | Page : 80-88
Classification and diagnosis of the inherited neuropathies
Mary M Reilly
Department of Molecular Neurosciences, MRC Centre for Neuromuscular Disease, National Hospital for Neurology and Neurosurgery and Institute of Neurology, Queen Square, London WC1N 3BG, United Kingdom
|Date of Submission||08-Feb-2009|
|Date of Acceptance||20-Mar-2009|
|Date of Web Publication||1-Jul-2009|
Mary M Reilly
National Hospital for Neurology and Neurosurgery and Institute of Neurology, Queen Square, London WC1N 3BG
|How to cite this article:|
Reilly MM. Classification and diagnosis of the inherited neuropathies. Ann Indian Acad Neurol 2009;12:80-8
| Introduction|| |
The inherited neuropathies are a clinically and genetically heterogeneous group of neuropathies in which an accurate genetic diagnosis is increasingly becoming possible. The identification of more than 30 causative genes for the inherited neuropathies has raised important questions regarding the approach to their diagnosis. The move towards developing gene-specific therapies will make accurate genetic diagnoses even more important.
The inherited neuropathies can broadly be classified into two groups: Those in which the neuropathy is the sole or primary part of the disease (e.g., Charcot-Marie-Tooth disease More Details, CMT) and those in which the neuropathy is part of a more generalized neurological or multisystem disorder [Table 1]. The latter group encompasses a very large group of disorders and although there have been major advances in both the diagnosis and the treatment of some of these disorders (e.g., liver transplantation for familial amyloid polyneuropathy, FAP), this review will concentrate on CMT and the related disorders of hereditary sensory and autonomic neuropathy (HSAN) and distal hereditary motor neuropathy (dHMN), as these are the commonest worldwide.
| Classification|| |
Although many of the causative genes have been identified for CMT, a purely genetic classification is not yet possible or practical. Current classifications [Table 2] combine the traditional neurophysiological classification with the more recently identified genes and although these classifications are not entirely satisfactory they are useful to clinicians in practice. CMT is traditionally classified into two types: CMT1 (demyelinating) and CMT2 (axonal); this classification is based on upper limb (median or ulnar nerve) motor conduction velocities (MCV), with CMT1 defined as those cases where MCV is less than 38 m/s and CMT2 as those where MCV is more than 38 m/s.  Historically, CMT was more commonly called hereditary motor and sensory neuropathy (HMSN) but CMT is the preferred term currently. HMSNI and HMSNII are identical to CMT1 and CMT2, respectively. In the HMSN classification, severely affected infants with the demyelinating form were classified as having HMSNIII (also called congenital hypomyelinating neuropathy (CHN) or Dejerine-Sottas neuropathy More Details (DSN)). This group of diseases was thought to be autosomal recessive (AR) but since many of these patients actually have de novo dominant (AD) mutations in the genes that commonly cause AD CMT1, we now use the terms CHN or DSN for this group and hence there is no CMT3. There are AR forms of both CMT1 and CMT2 and, confusingly, the AR forms of CMT1 are now called CMT4, while the much more rare AR CMT2 cases are generally referred to as AR CMT2. [Table 2] is a summary of the currently known main CMT genes (space constraints do not allow all loci to be included).
Hereditary sensory and autonomic neuropathy (HSAN) describes forms of inherited neuropathies in which sensory (and, in some types, autonomic) involvement predominates [Table 3]; distal hereditary motor neuropathies (dHMN) describe purely motor forms [Table 4].
This classification system is not perfect, and as we identify the causative genes it is clear that there is overlap between various types of CMT / HSAN / dHMN. For example, HSAN1 and CMT2B are clinically difficult to differentiate despite being caused by mutations in different genes, and certain genes for dHMN ( GARS , HSP27 , and HSP22 ) also cause axonal CMT.
| Is the neuropathy genetic?|| |
The first step in making the diagnosis of CMT is to determine whether the patient has a genetic neuropathy. Sometimes the answer is clear; for example, when there is an affected parent and child, either autosomal dominant (AD) or X-linked (if there is no definite male- to-male transmission) inheritance is probable, or when there are affected siblings from a consanguineous marriage, autosomal recessive (AR) inheritance is likely. X-linked inheritance should always be kept in mind unless there is unequivocal evidence of male-to-male transmission, especially as families are often not large enough to confidently rule this possibility out. In other patients, recognizing CMT can be more difficult. There may be no family history or families may be small and extensive family histories may not be available. Clinical features that may help the clinician decide whether the neuropathy is genetic include presentations in infancy; a long, slow progression; the presence of foot deformities; and, in adults, the lack of positive sensory symptoms (e.g., dysaesthesias or paresthesias) in the presence of clear sensory signs. If the clinical features raise the possibility, it is important not to rule out an inherited neuropathy, even in the absence of a family history.
| Cmt|| |
CMT is a common condition, with an estimated prevalence of 1 in 2500 in the general population.  This figure may be an underestimate as the true prevalence figures for CMT2 are not available at present since 75% of the causative genes are not yet known. As stated earlier, CMT is usually classified as either demyelinating (CMT1) or axonal (CMT2) [Table 2]. The MCVs in the upper extremities are usually uniformly slow in demyelinating CMT, whereas there is often patchy, asymmetric slowing, with conduction block and dispersion, in acquired demyelinating neuropathies (e.g., acute or chronic inflammatory demyelinating polyradiculoneuropathy). , This can be a helpful pointer diagnostically. Intermediate forms of CMT, with median or ulnar nerve MCVs between 25-45 m/s, are also present and may help direct the genetic diagnosis (see below). Sporadic cases of CMT occur often and are usually found to have mutations in the common AD genes (autosomal dominant or de novo dominant) or in the AR genes. The occurrence of de novo dominant mutations explains how the parents of these patients are found to be normal (clinically, neurophysiologically, and genetically). These cases are, however, very important to diagnose because they are de novo dominant, meaning that the children of these patients have a 50% risk of inheriting the mutant gene unlike the children of a patient with AR mutations. In most UK / North European and US populations, about 90% of cases of CMT are either AD or X-linked, whereas in countries with a higher rate of consanguineous marriages, AR CMT can account for up to 40%.  The diagnostic approach will therefore vary in specific countries and in specific ethnic groups. In all populations, CMT1 is consistently reported to be more common than CMT2 but, as previously stated, 75% of the genes have yet to be identified for CMT2 and therefore the true prevalence of CMT2 is unknown.
AD CMT1: Autosomal dominant demyelinating CMT
AD CMT1 is the most common form of CMT in most populations. Patients usually present with a 'classical CMT phenotype' that includes lower limb motor symptoms (e.g., difficulty in walking) beginning in the first two decades, along with distal weakness, atrophy, sensory loss, hyporeflexia, and foot deformity, e.g., pes cavus [Figure 1]. It is unusual for patients to present with sensory symptoms. It is also often difficult to accurately ascertain the age of onset as the symptoms in the first decade of life may be nonspecific (e.g., poor at sports, last in races, clumsiness). Patients usually have normal life spans, frequently need ankle-foot orthotics (AFOs), and rarely require wheelchairs for routine ambulation. The upper limbs are involved later than the lower limbs and it is very common for the patients not to complain of hand weakness (although it is detectable on examination) unless asked specific questions (e.g., do you have difficulty doing your buttons and zips or unscrewing the tops of bottles?). Median and ulnar MCVs are below 38 m/s and the sensory action potentials (SAPs) are either reduced or absent. Nerve biopsy demonstrates demyelination and onion bulb formation [Figure 2]. However, biopsies are no longer necessary to make the diagnosis.
The approach to the genetic diagnosis of AD CMT1 requires careful clinical examination, neurophysiological testing, and an appreciation of the frequency with which a particular gene causes AD CMT1 [Table 2],[Figure 3]. As a general rule, most AD CMT1 patients have a classical phenotype and the approach to the genetic diagnosis is therefore based primarily on the frequency of the underlying genetic causes. Classic CMT phenotypes and MCV less than 38 m/s (commonly around 20 m/s) are strongly suggestive of CMT1A, which is caused by a 1.4- Mb duplication on 17p11.2. , Sporadic cases occur in about 10% of CMT1A cases . Thus the lack of family history does not exclude CMT1A. In European populations CMT1A accounts for 70% of all CMT1 cases.  This frequency may be less in populations with a high rate of consanguinity, where AR CMT1 cases may have an increased frequency. The 1.4-Mb duplication contains the PMP22 gene, meaning that patients with this form of CMT1A have three copies of the PMP22 gene and this increased dose of PMP22 is the cause of this type of CMT1A. Mutations in the PMP22 gene can also cause CMT1, but with a wider spectrum of phenotypes, including classical CMT1A but also the more severe DSN. In addition, certain mutations can cause hereditary neuropathy with liability to pressure palsies (HNPP) (see below).
CMT1B caused by mutations in myelin protein zero (MPZ) comprise about 10% of AD CMT1 and are therefore the second commonest type. Patients can present with the classical CMT1 phenotype but are more likely to have either a more severe early-onset form of CMT with MCV < 10 m/s or a late-onset form with median MCVs in the axonal range. 
EGR2 and SIMPLE mutations are rare (< 1%) causes of AD CMT1. , Patients with EGR2 mutations usually present with the more severe DSN phenotype and patients with SIMPLE mutations frequently resemble those with CMT1A. Mutations in NEFL were originally described as a cause of CMT2,  but some patients have MCVs in the demyelinating range  in spite of the fact that the gene is expressed in neurons but not Schwann cells.
HNPP is an AD neuropathy usually caused by a deletion of the same 1.4-Mb portion of chromosome 17 that is duplicated in CMT1A.  Therefore, patients have only one copy of PMP22 , and this decreased dose of PMP22 is the cause of HNPP. Nonsense or frameshift mutations that truncate PMP22 and effectively cause a loss of function of one copy of PMP22 are rare causes of HNPP. Patients typically present with transient, recurrent episodes of focal weakness or sensory loss, usually precipitated by pressure in the distribution of individual nerves or plexuses.  Peripheral nerves that are susceptible to pressure along their routes are most commonly involved (e.g., the common peroneal nerve at the fibular head or the ulnar nerve at the elbow). Nerve conduction studies often show focal areas of slowing around sites subject to compression.  Screening patients with isolated pressure palsies (such as carpal tunnel syndrome) for HNPP is not warranted as to date all patients shown to have the genetic abnormality have had widespread nerve conduction abnormalities, even if they have involvement of only one nerve clinically.
X-linked CMT1 is the second commonest form of CMT and is caused by mutations in the gap junction protein beta 1 (GJB1) gene encoding connexin 32 (Cx32).  As expected with an X-linked disorder, males are usually more severely affected than females. Females may be very mildly affected and even asymptomatic though signs can usually be elicited. Cx32 is expressed in myelinating Schwann cells, not in neurons.  Nerve conduction is commonly slower in males (demyelinating CMT1 range) than in females, who are usually in the axonal CMT range; however, in both males and females the NCVs can often be in the intermediate range (25-40 m/s).  Occasional CMT1X patients have asymmetric MCVs reminiscent of CIDP.  Although oligodendrocytes also express Cx32, the CNS is most often only occasionally involved in CMT1X and usually asymptomatically (e.g., the only abnormalaties present may be extensor plantars, mild deafness, abnormal brainstem evoked potentials).  However, occasionally transient severe CNS involvement characterized by ataxia and dysarthria has been described.  There are over 300 causative GJB1 mutations ( http://www.molgen.ua.ac.be/CMTMutations/default.cfm ). Unlike distinct PMP22 and MPZ mutations, virtually all GJB1 mutations have similar age-related phenotypes that resemble those in which the gene is entirely deleted. 
AD CMT2: Autosomal dominant axonal CMT
AD CMT2 can be difficult to distinguish from an idiopathic axonal neuropathy when there is no family history. This is particularly a problem in older patients presenting with an incidental idiopathic axonal neuropathy that is mild and long-standing and with no family history or no family members available for examination. Eight causative genes have been identified [Table 2], which account for about 25% of all AD CMT2 cases.
Unlike AD CMT1, AD CMT2 can be subdivided into three distinct phenotypes [Figure 2]. The first and most common one is the 'classical CMT' phenotype. This is indistinguishable from the classical AD CMT1 phenotype until neurophysiological testing is done, although much later ages of onset may sometimes be seen in AD CMT2 than in AD CMT1. Nerve biopsies are rarely helpful diagnostically, showing only an axonal neuropathy without any specific diagnostic features. Mutations in mitofusin 2 (MFN2) cause CMT2A  which represents about 20% of all AD CMT2 cases. Although MFN2 is usually the first gene screened in classical AD CMT2, CMT2A patients with MFN2 mutations generally have a severe phenotype that may severely impair them in childhood. Twenty percent of MFN2 mutations are de novo. Occasional CMT2A patients also have optic atrophy (these cases were termed HMSN VI in previous classifications)  brisk reflexes, and / or minor white matter changes on brain MRI.  Mutations in MPZ and NEFL can also cause the classical AD CMT2 phenotype as mentioned above. Small heat shock protein genes HSP27 (HSPB1) and HSP22 (HSPB8) are rare causes of the classical AD CMT2 phenotype, but such cases usually have minimal sensory involvement. These two genes can also cause a purely motor phenotype, dHMN type II.  A homozygous mutation in HSP27 has also recently been described to cause AR CMT2. 
Profound sensory impairment, often including 'ulceromutilations,' characterizes the second AD CMT2 phenotype.  Unlike the classical CMT phenotype, these patients present with lack of sensation and the complications of sensory loss, including ulcerations, osteomyelitis, and amputations. Motor involvement is present but is usually less than the sensory involvement. The causative gene is RAB7 and patients are classified as having CMT2B.  CMT2B patients are difficult to distinguish from those with HSAN1 caused by mutations in the SPTLC1 gene although, unusually for hereditary neuropathy patients, the patients with SPTLC1 mutations often have neuropathic pain. , If patients present with prominent sensory features, both the RAB7 and SPTLC1 genes should be initially screened.
The third phenotype described in AD CMT2 is exemplified in patients with CMT2D. Unlike the classical length-dependent CMT patients, who present with lower limb involvement first, these patients present with atrophy and weakness of the small muscles of the hand (which can be unilateral and may be misdiagnosed as thoracic outlet syndrome); much later, there is involvement of the distal lower limb muscles. CMT2D is caused by mutations in GARS.  Some patients have no sensory involvement and have been classified as dHMN type V, an allelic condition. The dHMN V/CMT2D phenotype has subsequently been shown to be more commonly due to mutations in the BSCL2 gene,  which usually causes Silver syndrome (spastic legs and distal amyotrophy of the upper limbs) but can present (in 33% of cases) with just amyotrophy of the upper limbs. Therefore, in patients presenting with AD CMT2 and predominant involvement of the small hand muscles, BSCL2 and GARS should be screened first.
Autosomal recessive CMT
In most communities AR CMT is less common than AD CMT. AR CMT1 is also classified as CMT4, whereas AR CMT2 is usually just called AR CMT2. Thirteen genes have been identified that cause AR CMT4 (including three genes - PMP22, MPZ , and EGR2 - that also cause AD CMT1) [Table 2]. No one algorithm is suitable for the evaluation of CMT4, but there are simple clinical rules that can be helpful in diagnosis. Usually CMT4 cases have early, infantile onset (DSN or CHN) and are severe. Weakness often progresses to involve proximal muscles and may result in early loss of ambulation. Unlike most cases of AD CMT1, nerve biopsies can be useful in certain cases because specific features make a particular genetic diagnosis more likely (see below). Certain clinical features and the patient's ethnic background may help direct genetic diagnosis [Table 2].
In assessing AR CMT patients, particular points to consider include:
Identifying demyelination by MCV can be difficult in CMT4 because motor and sensory amplitudes are often unobtainable at routine recording sites as the patients are too severely affected. Conduction studies of nerves innervating proximal muscles may be necessary to identify slow MCV. Nerve biopsies are sometimes done in these circumstances to help clarify the type of CMT.
Nerve biopsies showing focally folded myelin are characteristic of CMT4B1 ( MTMR2 mutations) and CMT4B2 ( MTMR13 mutations) but can also be seen with MPZ mutations and in CMT4F secondary to periaxin mutations.
Severe and early scoliosis may be seen with CMT4C due to mutations in the KIAA1985 gene. Characteristic nerve biopsy features including basal membrane onion bulbs and multiple cytoplasmic processes of the Schwann cells ensheathing unmyelinated axons are also seen with KIAA1985 mutations. 
Three forms of AR CMT are largely confined to patients of Balkan gypsy origin. CMT4D secondary to NDRG1 mutations is characterized by a demyelinating neuropathy with a high prevalence of deafness. Tongue atrophy has also been described. CCFDN (congenital cataract, facial dysmorphism, and neuropathy syndrome) secondary to CTDP1 mutations is also found in gypsies. A third form of AR CMT1 has been described in Balkan gypsies (HMSN Russe) but the gene has yet to be identified.
Predominant sensory involvement and variable phenotypes are characteristic of CMT4F (periaxin mutations).
AR CMT2 is very rare compared to AD CMT2. Only two causative genes have been identified ( LMNA and GDAP1 ) [Table 2]. GDAP1 mutations are also the commonest cause of CMT4, a demyelinating form of AR CMT and therefore GDAP1 is often the first gene screened in most forms of AR CMT. Most patients with mutations in lamin A/C ( LMNA )  present in the second decade with a severe CMT phenotype, including proximal muscle involvement, although some have a milder phenotype. Lamin A/C mutations have been associated with a wide spectrum of other phenotypes, including Emery-Dreifuss muscular dystrophy More Details, cardiomyopathy, and Dunnigan- type familial partial lipodystrophy.
Certain forms of CMT characteristically present with MCVs in the intermediate range (25-45 m/s) These include dominant intermediate (DI)-CMTB caused by DNM2 mutations;  DI-CMTC caused by YARS mutations;  and DI-CMTA, in which only linkage has been identified at 10q24.1-25.1. In addition, as discussed above, patients with CMT1X ( GJB 1 mutations), CMT2E ( NEFL mutations), late-onset CMT1B ( MPZ mutations), and CMT4A ( GDAP1 mutation) often present with intermediate MCVs.
| Hereditary sensory and autonomic neuropathy|| |
The hereditary sensory and autonomic neuropathies are rarer than CMT but many of the genes have been identified [Table 3]. Autonomic abnormalities are often minimal in these conditions [hence certain forms are sometimes referred to as hereditary sensory neuropathies (HSN)] and motor involvement can be present. The sensory loss can lead to severe complications, including recurrent injuries, ulcerations, osteomyelitis, and amputations. The commonest AD form is HSAN1 (or HSN1) caused by SPTLC1 mutations. Patients usually present in the second decade with distal lower limb sensory loss and many have neuropathic pain as described above. Motor involvement can be significant, especially later in the disease course, making it difficult to distinguish this disorder from certain forms of CMT2. MCVs can be in the demyelinating range, with males being more severely affected than females.  As discussed above, this disease is very difficult to differentiate from CMT2B secondary to RAB7 mutations although the lancinating pain in patients with SPTLC1 mutations can be a useful guide to this diagnosis.
HSAN II is an early-onset, autosomal recessive, severe sensory neuropathy with prominent sensory complications; it is due to mutations in the HSN2 gene.
HSAN 111 (Riley-Day syndrome) is an AR neuropathy seen in Ashkenazi Jews and is characterized by mainly autonomic involvement, though it also involves the peripheral nervous system, particularly the sensory nerves. The causative gene is the IKBKAP gene. The predominant autonomic features make this type relatively easy to distinguish from the other forms of HSAN.
HSAN IV and V are both AR neuropathies characterized by congenital insensitivity to pain. HSAN IV [also called congenital insensitivity to pain with anhidrosis (CIPA)] presents with a severe sensory neuropathy, anhidrosis, and mental retardation and is due to mutations in the NTRK1 gene. HSAN V is similar, though without the mental retardation or significant anhidrosis, and has been shown to result from mutations in NTRK1 and also NGFB .
Recently, the identification of homozygous mutations in the SCN9A gene as a rare cause of congenital insensitivity to pain  has been of great interest because heterozygous mutations in the same gene cause hereditary erythermalgia  and paroxysmal extreme pain disorders.  The finding of mutations in a channelopathy gene in these painful neuropathies will hopefully expand the potential therapeutic possibilities.
| Distal hereditary motor neuropathies|| |
The dHMNs are a complex group of disorders [Table 4] that typically present with length-dependent weakness and no sensory loss. They can be indistinguishable from certain forms of CMT until neurophysiology confirms normal sensory action potentials, as some CMT patients have not only no sensory symptoms but also no sensory signs. DHMN II is the classic form of AD dHMN and is due to mutations in the HSP27 and HSP22 genes, which also cause CMT2F and CMT2L. There are many other forms, but the genes are not known for all types. The main types, other then dHMN II, are summarized below:
Mutations in GARS and BSCL2 cause dHMN V (also CMT2D), which is characterized by onset in the upper limbs as described above.
DHMN VI, an unusual severe AR form of dHMN, presents in infancy with respiratory and distal limb involvement (called spinal muscle atrophy with respiratory distress type 1). This is due to mutations in IGHMBP2 .
Mutations in dynactin ( DCTN1 ) cause one form of dHMN type VII, which is characterized by vocal cord paralysis and progressive weakness and atrophy of the face, hands and legs.
Missense mutations in sena t axin ( SETX ) can cause a form of dHMN with pyramidal features whereas nonsense mutations in the same gene cause AR ataxia oculomotor apraxia type 2 (AOA2).
| Conclusion|| |
The hereditary neuropathies are clinically and genetically heterogeneous. Although the area is complex and the number of causative genes is increasing rapidly, algorithms to guide genetic testing for the more common AD disorders and careful phenotyping for the rare AR disorders should help diagnosis. Neurophysiological testing remains crucial in aiding diagnosis. One of the major issues throughout the world is the lack of availability of testing for the rarer genes. It cannot be emphasized how important an accurate genetic diagnosis is for these patients. There are obvious benefits; for example, diagnostic testing for other family members can be done, accurate genetic counseling and prognostication becomes possible, as also predictive testing, antenatal testing, and preimplantation diagnosis. Furthermore, an accurate diagnosis means that patients need not have invasive diagnostic tests, e.g., nerve biopsies and lumbar punctures. In certain situations where inflammatory neuropathies are being considered, a genetic diagnosis can also prevent a trial of potentially dangerous immunosuppressive therapy. Finally, the era of specific treatment for genetic neuropathies is now here. The first therapeutic trials are ongoing (ascorbic acid for CMT1A) and because any treatments developed are likely to be gene specific, the case for an accurate genetic diagnosis will become even more convincing.[Figure 4]
| Acknowledgments|| |
MMR acknowledges the Medical Research Council and the Muscular Dystrophy Campaign for funding support. MMRs work was undertaken at University College London Hospitals/ University College London, which received a proportion of funding from the Department of Health's National Institute for Health Research Biomedical Research Centre's funding scheme.
| References|| |
|1.||Reilly MM. Sorting out the inherited neuropathies. Pract Neurol 2007;7:93-105. |
|2.||Skre H. Genetic and clinical aspects of Charcot-Marie-Tooth′s disease. Clin Genet 1974;6:98-118. |
|3.||Lewis RA, Sumner AJ. The electrodiagnostic distinctions between chronic familial and acquired demyelinative neuropathies. Neurology 1982;32:592-6. |
|4.||Lewis RA, Sumner AJ, Shy ME. Electrophysiological features of inherited demyelinating neuropathies: A reappraisal in the era of molecular diagnosis. Muscle Nerve 2000;23:1472-87. |
|5.||Dubourg O, Azzedine H, Verny C, Durosier G, Birouk N, Gouider R, et al . Autosomal-recessive forms of demyelinating Charcot- Marie- Tooth disease. Neuromolecular Med 2006;8:75-86. |
|6.||Lupski JR, de Oca-Luna RM, Slaugenhaupt S, Pentao L, Guzzetta V, Trask BJ, et al . DNA duplication associated with Charcot-Marie- Tooth disease type 1A. Cell 1991;66:219-32. |
|7.||Raeymaekers P, Timmerman V, Nelis E, De Jonghe P, Hoogendijk JE, Baas F, et al . Duplication in chromosome 17p11.2 in Charcot-Marie-Tooth neuropathy type 1a (CMT 1a). The HMSN Collaborative Research Group. Neuromuscul Disord 1991;1:93-7. |
|8.||Nelis E, Van Broeckhoven C, De Jonghe P, Lφfgren A, Vandenberghe A, Latour P, et al . Estimation of the mutation frequencies in Charcot-Marie-Tooth disease type 1 and hereditary neuropathy with liability to pressure palsies: A European collaborative study. Eur J Hum Genet 1996;4:25-33. |
|9.||Shy ME, Jαni A, Krajewski K, Grandis M, Lewis RA, Li J, et al . Phenotypic Clustering in MPZ mutations. Brain 2004;127:371-84. |
|10.||Warner LE, Mancias P, Butler IJ, McDonald CM, Keppen L, Koob KG, et al . Mutations in the early growth response 2 (EGR2) gene are associated with hereditary myelinopathies. Nat Genet 1998;18:382-4. |
|11.||Street VA, Bennett CL, Goldy JD, Shirk AJ, Kleopa KA, Tempel BL, et al . Mutation of a putative protein degradation gene LITAF/SIMPLE in Charcot-Marie-Tooth disease 1C. Neurology 2003;60:22-6. |
|12.||Mersiyanova IV, Perepelov AV, Polyakov AV, Sitnikov VF, Dadali EL, Oparin RB, et al . A new variant of Charcot-Marie- Tooth disease type 2 is probably the result of a mutation in the neurofilament-light gene. Am J Hum Genet 2000;67:37-46. |
|13.||Sevilla T, Vνlchez JJ. [Different phenotypes of Charcot-Marie-Tooth disease caused by mutations in the same gene. Are classical criteria for classification still valid?]. Neurologia 2004;19:264-71. |
|14.||Chance PF, Alderson MK, Leppig KA, Lensch MW, Matsunami N, Smith B, et al . DNA deletion associated with hereditary neuropathy with liability to pressure palsies. Cell 1993;72:143-51. |
|15.||Li J, Krajewski K, Lewis RA, Shy ME. Loss-of-function phenotype of hereditary neuropathy with liability to pressure palsies. Muscle Nerve 2004;29:205-10. |
|16.||Li J, Krajewski K, Shy ME, Lewis RA. Hereditary neuropathy with liability to pressure palsy: The electrophysiology fits the name. Neurology 2002;58:1769-73. |
|17.||Bergoffen J, Scherer SS, Wang S, Scott MO, Bone LJ, Paul DL, et al . Connexin mutations in X-linked Charcot-Marie-Tooth disease. Science 1993;262:2039-42. |
|18.||Kleopa KA, Scherer SS. Molecular genetics of X-linked Charcot-Marie-Tooth disease. Neuromolecular Med 2006;8:107-22. |
|19.||Lewis RA, Shy ME. Electrodiagnostic findings in CMTX: A disorder of the Schwann cell and peripheral nerve myelin. Ann N Y Acad Sci 1999;883:504-7. |
|20.||Mitchell A, Blake J, Laura M, et al. GJB1 gene mutations in suspected inflammatory demyelinating neuropathies not responding to treatment. (letter). JNPP (in press). |
|21.||Kleopa KA, Yum SW, Scherer SS. Cellular mechanisms of connexin32 mutations associated with CNS manifestations. J Neurosci Res 2002;68:522-34. |
|22.||Paulson HL, Garbern JY, Hoban TF, Krajewski KM, Lewis RA, Fischbeck KH, et al . Transient central nervous system white matter abnormality in X-linked Charcot-Marie-Tooth disease. Ann Neurol 2002;52:429-34. |
|23.||Shy ME, Siskind C, Swan ER, Krajewski KM, Doherty T, Fuerst DR, et al . CMT1X phenotypes represent loss of GJB1 gene function. Neurology 2007;68:849-55. |
|24.||Züchner S, Mersiyanova IV, Muglia M, Bissar-Tadmouri N, Rochelle J, Dadali EL, et al . Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nat Genet 2004;36:449-51. |
|25.||Züchner S, De Jonghe P, Jordanova A, Claeys KG, Guergueltcheva V, Cherninkova S, et al . Axonal neuropathy with optic atrophy is caused by mutations in mitofusin 2. Ann Neurol 2006;59:276-81. |
|26.||Chung KW, Kim SB, Park KD, Choi KG, Lee JH, Eun HW, et al . Early onset severe and late-onset mild Charcot-Marie-Tooth disease with mitofusin 2 (MFN2) mutations. Brain 2006;129:2103-18. |
|27.||Irobi J, Dierick I, Jordanova A, Claeys KG, De Jonghe P, Timmerman V. Unraveling the genetics of distal hereditary motor neuronopathies. Neuromolecular Med 2006;8:131-46. |
|28.||Houlden H, Laura M, Wavrant-De Vriθze F, Blake J, Wood N, et al . Mutations in the HSP27 (HSPB1) gene cause dominant, recessive, and sporadic distal HMN/CMT type 2. Neurology 2008;71:1660-8. |
|29.||Auer-Grumbach M, De Jonghe P, Verhoeven K, Timmerman V, Wagner K, Hartung HP, et al . Autosomal dominant inherited neuropathies with prominent sensory loss and mutilations: A review. Arch Neurol 2003;60:329-34. |
|30.||Verhoeven K, De Jonghe P, Coen K, Verpoorten N, Auer- Grumbach M, Kwon JM, et al . Mutations in the small GTP- ase late endosomal protein RAB7 cause Charcot-Marie-Tooth type 2B neuropathy. Am J Hum Genet 2003;72:722-7. |
|31.||Dawkins JL, Hulme DJ, Brahmbhatt SB, Auer-Grumbach M, Nicholson GA. Mutations in SPTLC1, encoding serine palmitoyltransferase, long chain base subunit-1, cause hereditary sensory neuropathy type I. Nat Genet 2001;27:309-12. |
|32.||Bejaoui K, Wu C, Scheffler MD, Haan G, Ashby P, Wu L, et al . SPTLC1 is mutated in hereditary sensory neuropathy, type 1. Nat Genet 2001;27:261-2. |
|33.||Antonellis A, Ellsworth RE, Sambuughin N, Puls I, Abel A, Lee-Lin SQ, et al . Glycyl tRNA synthetase mutations in Charcot- Marie- Tooth disease type 2D and distal spinal muscular atrophy type V. Am J Hum Genet 2003;72:1293-9. |
|34.||Rohkamm B, Reilly MM, Lochmüller H, Schlotter-Weigel B, Barisic N, Schφls L, et al . Further evidence for genetic heterogeneity of distal HMN type V, CMT2 with predominant hand involvement and Silver syndrome. J Neurol Sci 2007;263:100-6. |
|35.||Gabreλls-Festen A, van Beersum S, Eshuis L, LeGuern E, Gabreλls F, van Engelen B, et al . Study on the gene and phenotypic characterisation of autosomal recessive demyelinating motor and sensory neuropathy (Charcot-Marie-Tooth disease) with a gene locus on chromosome 5q23-q33. J Neurol Neurosurg Psychiatry 1999;66:569-74. |
|36.||De Sandre-Giovannoli A, Chaouch M, Kozlov S, Vallat JM, Tazir M, Kassouri N, et al . Homozygous defects in LMNA, encoding lamin A/C nuclear-envelope proteins, cause autosomal recessive axonal neuropathy in human (Charcot-Marie-Tooth disorder type 2) and mouse. Am J Hum Genet 2002;70:726-36. |
|37.||Züchner S, Noureddine M, Kennerson M, Verhoeven K, Claeys K, De Jonghe P, et al . Mutations in the pleckstrin homology domain of dynamin 2 cause dominant intermediate Charcot-Marie-Tooth disease. Nat Genet 2005;37:289-94. |
|38.||Jordanova A, Irobi J, Thomas FP, Van Dijck P, Meerschaert K, Dewil M, et al . Disrupted function and axonal distribution of mutant tyrosyl-tRNA synthetase in dominant intermediate Charcot-Marie-Tooth neuropathy. Nat Genet 2006;38:197-202. |
|39.||Houlden H, King R, Blake J, Groves M, Love S, Woodward C, et al . Clinical, pathological and genetic characterization of hereditary sensory and autonomic neuropathy type 1 (HSAN I). Brain 2006;129:411-25. |
|40.||Cox JJ, Reimann F, Nicholas AK, Thornton G, Roberts E, Springell K, et al . An SCN9A channelopathy causes congenital inability to experience pain. Nature 2006;444:894-8. |
|41.||Yang Y, Wang Y, Li S, Xu Z, Li H, Ma L, et al . Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia. J Med Genet 2004;41:171-4. |
|42.||Fertleman CR, Baker MD, Parker KA, Moffatt S, Elmslie FV, Abrahamsen B, et al . SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes. Neuron 2006;52:767-74. |
[Figure 1], [Figure 2], [Figure 3], [Figure 4]
[Table 1], [Table 2], [Table 3], [Table 4]
|This article has been cited by|
|| result 1 Document Congenital insensitivity to pain and anhidrosis: A case report from South India
| || Authors of Document Udayashankar, C., Oudeacoumar, P., Nath, A.K. |
| ||Source of the Document Indian Journal of Dermatology. 2012; |
||Nerve conduction studies and needle EMG in very small children
| ||Matthew C. Pitt |
| ||European Journal of Paediatric Neurology. 2011; |